Medical diagnoses of many diseases only recently became possible with the availability of magnetic resonance imaging (MRI). According to the Organization for Economic Cooperation and Development, the utilization rate for MR imaging in 2016 was reported to be 12% of the population of the United States (i.e ~ 38 million MRI scan) among which approximately 70% of those (i.e ~ 27 million) were performed using magnetic contrast agents (CA). 
The market has been facing a growing concern over the toxicity of Gadolinium (Gd) based contrast agents. Health risks caused by Gd separation from the chelated Gd depositions include fatal diseases such as nephrogenic systemic fibrosis (NSF).
Technology Overview
This technology comprises a solution for addressing the issues with contrast agent toxicity currently facing the MRI market in the imaging of liver cancers: an Mn-based contrast agent derived from superparamagnetic Mn-ferrite nanoparticles. 
Several key steps have been developed and reduced to practice, including the protocols for the processing of SPM Mn-ferrite NPs, chelation of NPs, the use of EXAFS to monitor the distribution of cations within the ferrite unit cell, and early success in the tailored distribution of cations within the unit cell.
- Experiences low levels of toxicity, allowing for higher dosages, and allowing for higher imaging efficacy
- MFONPs can be made having the appropriate diameter, size distribution, and shape necessary for images and MHT applications without detrimental declustering
- MFONPs offers superior contrast imaging in comparison to the existing Gd complexes in the marketplace
- Cell therapy
- License
- Partnering
- Research Collaboration
Patent Information:
For Information, Contact:
Colin Sullivan
Commercialization Consultant
Northeastern University
Parisa Andalib
John Scudiere
Vincent Harris
manganese ferrite
MRI contrast agent
superparamagnetic nanoparticles